Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

Plans To Commence World-First Phase 1b First-In-Human (FIH) Study of PRP Q1, 2027MELBOURNE, Australia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. NASDAQ:PPCB (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, includ…